| Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts P Saharinen, L Eklund, J Miettinen, R Wirkkala, A Anisimov, M Winderlich, ... Nature cell biology 10 (5), 527-537, 2008 | 539 | 2008 |
| HSV‐1 ICP 27 targets the TBK 1‐activated STING signalsome to inhibit virus‐induced type I IFN expression MH Christensen, SB Jensen, JJ Miettinen, S Luecke, T Prabakaran, ... The EMBO journal 35 (13), 1385-1399, 2016 | 201 | 2016 |
| Global secretome characterization of herpes simplex virus 1-infected human primary macrophages JJ Miettinen, S Matikainen, TA Nyman Journal of virology 86 (23), 12770-12778, 2012 | 66 | 2012 |
| Monosodium urate activates Src/Pyk2/PI3 kinase and cathepsin dependent unconventional protein secretion from human primary macrophages E Välimäki, JJ Miettinen, N Lietzen, S Matikainen, TA Nyman Molecular & Cellular Proteomics 12 (3), 749-763, 2013 | 56 | 2013 |
| Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development P Saharinen, H Helotera, J Miettinen, C Norrmen, G D'Amico, M Jeltsch, ... Genes & development 24 (9), 875-880, 2010 | 40 | 2010 |
| Aminopeptidase expression in multiple myeloma associates with disease progression and sensitivity to melflufen JJ Miettinen, R Kumari, GA Traustadottir, ME Huppunen, P Sergeev, ... Cancers 13 (7), 1527, 2021 | 37 | 2021 |
| Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia H Kuusanmäki, O Dufva, M Vähä-Koskela, AM Leppä, J Huuhtanen, ... Blood 141 (13), 1610-1625, 2023 | 31 | 2023 |
| CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia W Grey, A Rio-Machin, P Casado, E Grönroos, S Ali, JJ Miettinen, ... Science translational medicine 14 (650), eabn3248, 2022 | 13 | 2022 |
| S100 calcium binding protein family members associate with poor patient outcome and response to proteasome inhibition in multiple myeloma M Liu, Y Wang, JJ Miettinen, R Kumari, MM Majumder, C Tierney, ... Frontiers in Cell and Developmental Biology, 2261, 2021 | 10 | 2021 |
| Melflufen efficacy in multiple myeloma with TP53 aberrations A Slipicevic, U Munawar, T Stühmer, J Aschan, F Lehmann, ... Cancer Research 80 (16_Supplement), 1843-1843, 2020 | 8 | 2020 |
| Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma A Bolomsky, JJ Miettinen, A Malyutina, A Besse, J Huber, S Fellinger, ... Blood advances 5 (20), 4125-4139, 2021 | 7 | 2021 |
| Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes P Casado, A Rio-Machin, JJ Miettinen, F Bewicke-Copley, ... Signal Transduction and Targeted Therapy 8 (1), 80, 2023 | 6 | 2023 |
| Identification of protein biomarker signatures for acute myeloid leukemia (AML) using both nontargeted and targeted approaches P Dowling, C Tierney, K Dunphy, JJ Miettinen, CA Heckman, D Bazou, ... Proteomes 9 (4), 42, 2021 | 6 | 2021 |
| The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death K Flanagan, R Kumari, JJ Miettinen, SL Haney, ML Varney, JT Williams, ... Hemasphere 6 (3), e687, 2022 | 4 | 2022 |
| Phosphoproteomic analysis of primary myeloma patient samples identifies distinct phosphorylation signatures correlating with chemo-sensitivity profiles in an ex vivo drug … K Dunphy, P Dowling, JJ Miettinen, CA Heckman, P Meleady, M Henry, ... Blood 138, 2666, 2021 | 3 | 2021 |
| In Vitro and in Vivo Activity of Melflufen in Amyloidosis K Flanagan, MM Majumder, R Kumari, J Miettinen, A Slipicevic, ... Blood 134, 3100, 2019 | 3 | 2019 |
| Activation of innate immune response in human macrophages by Herpes simplex virus-1 and crystallized monosodium urate J Miettinen Helsingin yliopisto, 2014 | 3 | 2014 |
| Proteomic and metabolomic analysis of bone marrow and plasma from patients with extramedullary multiple myeloma identifies distinct protein and metabolite signatures K Dunphy, D Bazou, M Henry, P Meleady, JJ Miettinen, CA Heckman, ... Cancers 15 (15), 3764, 2023 | 2 | 2023 |
| Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen A Gebraad, R Ohlsbom, JJ Miettinen, P Emeh, TK Pakarinen, M Manninen, ... Cells 11 (9), 1574, 2022 | 2 | 2022 |
| Predictive response biomarkers for BET inhibitors in AML JJ Saad, J Miettinen, D Tsallos, S Eldfors, M Kontro, K Wennerberg, ... Blood 132, 2749, 2018 | 2 | 2018 |
Caroline HeckmanUniversity of Helsinki, Institute for Molecular Medicine Finland FIMM-HiLIFEVerified email at helsinki.fi
